Replimune Misses EPS by $0.03; CEO Sells $510K Shares

For traders and market participants, Replimune's small EPS miss is less important than the stock's resilience near $15 and the unusual spread between the $11.86 consensus price target and the current price. The insider tax-selling at $12.97 provides a useful technical reference point.

Replimune Group (NASDAQ: REPL) released quarterly earnings results on Friday, August 14, 2026, reporting a net loss of $0.72 per share, a $0.03 miss against the Zacks consensus estimate of ($0.69). The stock opened at $14.97 that day, down $0.22 from the prior close, with trading volume of 2,398,241 shares against an average volume of 8,223,322. At a market capitalization of $1.26 billion and a 52-week range of $1.50 to $15.70, REPL sits within 5% of its 12-month high, a remarkable position for a clinical-stage biotech that still reports negative EPS. The company's quick ratio and current ratio both stand at 4.79, debt-to-equity is 0.63, beta is 0.88, and the trailing price-to-earnings ratio is negative at -4.75. Basic financial metrics indicate ample short-term liquidity and relatively low market sensitivity.

“

The average target lags the current share price by roughly 21%, reflecting older estimates that have not yet caught up with the stock's surge; the newest targets of $16 and $17 imply further upside of 7% to 14% from $14.97.

The earnings miss itself carries limited informational value for a pre-revenue oncology developer, where quarterly losses are primarily a function of R&D expense recognition and trial enrollment timing rather than commercial execution. More consequential is the recent wave of analyst rating changes. On May 23, Wall Street Zen upgraded REPL from strong sell to sell, the first step away from the most bearish stance. On June 30, BMO Capital Markets raised the company from underperform to outperform with a $16.00 price target. On August 4, Leerink Partners upgraded from market perform to outperform and lifted its price objective from $11.00 to $17.00. On August 7, Wedbush raised the stock from neutral to outperform with a $12.00 target, and Cantor Fitzgerald reiterated an overweight rating in a note the following Wednesday. MarketBeat data show one Strong Buy, six Buy, one Hold, and two Sell ratings, with an average rating of Moderate Buy and a consensus price target of $11.86. The average target lags the current share price by roughly 21%, reflecting older estimates that have not yet caught up with the stock's surge; the newest targets of $16 and $17 imply further upside of 7% to 14% from $14.97.

Insider activity has drawn attention but is almost entirely mechanical. CEO Sushil Patel sold 39,341 shares on Monday, August 10, at an average price of $12.97 for total proceeds of $510,252.77, a 5.26% reduction in his direct holdings. Konstantinos Xynos sold 11,447 shares at the same price for $148,467.59, a 4.86% reduction. A third insider, Christopher Sarchi, sold 12,000 shares. The SEC filings explicitly state these sales were made to cover tax withholding obligations related to the vesting of equity awards. Patel still directly owns 708,151 shares valued at approximately $9.18 million based on the $12.97 sale price. For a company whose shares have appreciated roughly tenfold from the 52-week low of $1.50, tax-withholding sales are a routine, non-discretionary event and should not be interpreted as a negative signal about the pipeline. The heavy insider selling over the last three months, totaling 81,868 shares, likely reflects similar vesting-related mechanics across multiple executives.